Stock screenerAll disclosures →
EDGAR →
DTIL
Conviction 34HealthcareScan · Thu, Jun 25, 2026DTIL$6.74+0.00%
ResistanceSupportVol 14Vol MA14 358.73K
Mar 26Apr 14May 1May 19Jun 8Jun 25
PRECISION BIOSCIENCES INCBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.precisionbiosciences.com ↗
Price6.74
Change+0.00%
Gap+0.89%
Rel volume1.18×
Avg volume355.47K
Avg $ vol2.37M
SMA 206.59
SMA 507.12
SMA 2005.68
Price vs 50-5.29%
Price vs 200+18.61%
MA stackmixed
50/200 cross—
Supertrenddown · 7.93
RSI (14)49
MACD hist0.06
MACD crossbull · 4d
Stoch %K / %D37 / 41
ADX (14)16
+DI / −DI25 / 18
RSI divergence—
MACD divergence—
ATR %+7.91%
ADR %8.19%
52w high8.61
52w low3.57
From 52w high-21.72%
Above 52w low+88.80%
New 52w highNo
SqueezeOn · 1d
Bollinger width19.61%
%B0.61
Donchian pos38.34%
Donchian high7.93
Donchian low6.00
AVWAP (52w high)5.86
vs AVWAP high+14.96%
AVWAP (52w low)6.36
vs AVWAP low+6.01%
OBV trendFlat
Chaikin MF (20)-0.36
Today vs 20d1.18×
Avg vol (14d)358.73K
Avg vol (20d)355.47K
Avg $ vol (20d)2.37M
Market cap173.91M
RS 3m (vs SPY)-6.94%
RS 6m (vs SPY)+42.38%
RS line new highNo
Trend template4/8
Technical rank62.4
1 week+3.69%
1 month-11.08%
3 months+4.17%
6 months+55.30%
1 year+47.48%
YTD+64.39%
P/E-3.80
P/B2.29
P/S5.08
P/FCF-2.64
EPS-3.56
Div yield—
ROE-60.08%
ROA-31.78%
Debt/Eq0.29
Current14.02
EV/EBITDA-1.91
Gross margin—
Net margin-133.45%
Rev growth-50.12%
EPS growth-737.98%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value96.81M
Revenue10.84M
Net income-18.44M
Gross profit—
Free cash flow-65.93M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out25.8M
Employees66
ListedThu, Mar 28, 2019
Free float24.26M
Float %94.0%
Short interest1.67M
Days to cover4.4d
Short volume55.6%
Squeeze score49 / 100
Next earningsThu, Aug 6, 2026 (42d)
EPS forecast−$0.71 · 2 est
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction34 / 100
Pattern quality—
Tech rank62.4 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance8.41
Support6.03
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in DTIL
No recent disclosed trades by Congress in DTIL. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in DTIL · 10 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Buehler Kevin Director · Restricted Stock Units · 2026-06-03 | Grant | 20.98K | $0 | 2026-06-03 | 2026-06-05 |
Frankel Stanley Director · Restricted Stock Units · 2026-06-03 | Grant | 20.98K | $0 | 2026-06-03 | 2026-06-05 |
Brown Melinda Director · Restricted Stock Units · 2026-06-03 | Grant | 20.98K | $0 | 2026-06-03 | 2026-06-05 |
Pire Shari Lisa Director · Restricted Stock Units · 2026-06-03 | Grant | 20.98K | $0 | 2026-06-03 | 2026-06-05 |
Germano Geno J Director · Restricted Stock Units · 2026-06-03 | Grant | 20.98K | $0 | 2026-06-03 | 2026-06-05 |
SMITH J. JEFFERSON Chief Research Officer · Restricted Stock Units · 2026-06-01 | Grant | 57.39K | $0 | 2026-06-01 | 2026-06-03 |
Amoroso Michael President and CEO · Restricted Stock Units · 2026-06-01 | Grant | 573.89K | $0 | 2026-06-01 | 2026-06-03 |
Kelly John Alexander Chief Financial Officer · Restricted Stock Units · 2026-06-01 | Grant | 193.69K | $0 | 2026-06-01 | 2026-06-03 |
Scimeca Dario General Counsel and Secretary · Restricted Stock Units · 2026-06-01 | Grant | 107.6K | $0 | 2026-06-01 | 2026-06-03 |
Pire Shari Lisa Director · Common Stock · 2026-05-20 | Exercise | 21K | — | 2026-05-20 | 2026-05-22 |
SEC filings
EDGAR filings in DTIL · 1 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.